Product Program year 2024 Source: CMS Open Payments

Natroba

Drug Head Lice

NDC 52246-929-04

Open in the dashboard

General payments

$123,463

17 payments

Research payments

$0

0 payments

Through program year 2024, $123,463 in general payments and $0 in research payments were reported against Natroba (Head Lice).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2024 General $38,759 12
2023 General $84,704 5

Breakdown

Who paid General payments · program years 2023–2024
  1. ParaPRO, LLC $123,463 17 payments
Top recipients General payments · program year 2024
  1. Scott Guenthner Dermatology · Plainfield, IN $17,200 44% · 1 payment
  2. Angela Pierce Nurse Practitioner · Indianapolis, IN $6,259 16% · 1 payment
  3. Sanjosh Singh Dermatology · Brooklyn, NY $3,600 9% · 1 payment
  4. Rawaa Almukhtar Dermatology · La Jolla, CA $2,500 6% · 1 payment
  5. Christopher Belcher Pediatric Infectious Diseases · Carmel, IN $2,250 6% · 1 payment

The top 5 of 12 recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Dermatology $25,100 65% · 4 practitioners
  2. Nurse Practitioner $6,259 16% · 1 practitioner
  3. Pediatric Infectious Diseases Pediatrics $2,250 6% · 1 practitioner
  4. Physician Assistant, Medical Physician Assistant $1,900 5% · 1 practitioner
  5. Family Medicine $1,750 5% · 3 practitioners

The top 5 of 7 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. Indiana $25,709 66% · 3 recipients
  2. New York $4,100 11% · 2 recipients
  3. Florida $2,900 7% · 2 recipients
  4. California $2,500 6% · 1 recipient
  5. Tennessee $1,800 5% · 1 recipient

The top 5 of 8 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

45

Prescriptions dispensed, refills included

Drug cost

$11,896

Paid at the pharmacy, in all

Prescribers

3

With 11 or more claims of it

Medicare Part D drugs matched to Natroba, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Natroba Spinosad Same name 3 45 $11,896

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

3 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
John Potomski Geriatric Medicine FL 19 $4,624 None on record
Axel Martinez Irizarry Family Practice FL 15 $4,345 None on record
Dmitry Khasak Dermatology NY 11 $2,927 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

17 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record